Cargando…
Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy
INTRODUCTION: Gastric cancer (GC) is one of the leading causes of cancer death worldwide. The membrane glycoprotein CD200, widely expressed on multiple cells/tissues, uses a structurally similar receptor (CD200R), delivering immunoregulatory signals. There is evidence that CD200/CD200R signaling sup...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209723/ https://www.ncbi.nlm.nih.gov/pubmed/30393481 http://dx.doi.org/10.5114/aoms.2018.73398 |
_version_ | 1783366956231950336 |
---|---|
author | Zgodziński, Witold Grywalska, Ewelina Surdacka, Agata Zinkiewicz, Krzysztof Majewski, Marek Szczepanek, Dariusz Wallner, Grzegorz Roliński, Jacek |
author_facet | Zgodziński, Witold Grywalska, Ewelina Surdacka, Agata Zinkiewicz, Krzysztof Majewski, Marek Szczepanek, Dariusz Wallner, Grzegorz Roliński, Jacek |
author_sort | Zgodziński, Witold |
collection | PubMed |
description | INTRODUCTION: Gastric cancer (GC) is one of the leading causes of cancer death worldwide. The membrane glycoprotein CD200, widely expressed on multiple cells/tissues, uses a structurally similar receptor (CD200R), delivering immunoregulatory signals. There is evidence that CD200/CD200R signaling suppresses anti-tumor responses in different types of malignancies. Little is known about the CD200/CD200R pathway in GC. The aim of the study was to evaluate the frequencies of CD200+ and CD200R+ lymphocytes in patients with GC. MATERIAL AND METHODS: Forty patients primarily diagnosed with GC and 20 healthy volunteers (control group) were enrolled. The viable peripheral blood lymphocytes underwent labeling with fluorochrome-conjugated monoclonal antibodies and were analyzed using a flow cytometer. RESULTS: In the GC group, the percentages of T CD3+, CD3+/CD4+, and CD3+/CD8+ cells expressing CD200 antigen were higher than in the control group (p < 0.00013, p < 0.0004, and p < 0.0006, respectively). In the GC group, the frequencies of T CD3+, CD3+/CD4+ and CD3+/CD8+ cells expressing CD200R were lower than in the control group (p < 0.0009, p < 0.004, and p < 0.002, respectively). The percentage of B CD19+/CD200+ lymphocytes was higher in GC patients than in the control group (p < 0.00005). Lower frequency of B CD19+/CD200R+ cells was observed in GC patients compared to the control group (p < 0.0001). No differences in the frequencies of CD200+ and CD200R+ lymphocytes were found in relation to either UICC stage or histological grading of the tumors. CONCLUSIONS: For GC pathogenesis, deregulation of the CD200/CD200R axis is important. High percentages of lymphocytes with CD200 expression may contribute to the continuous T cell activation and development of chronic inflammation and influence gastric carcinogenesis. |
format | Online Article Text |
id | pubmed-6209723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-62097232018-11-02 Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy Zgodziński, Witold Grywalska, Ewelina Surdacka, Agata Zinkiewicz, Krzysztof Majewski, Marek Szczepanek, Dariusz Wallner, Grzegorz Roliński, Jacek Arch Med Sci Basic Research INTRODUCTION: Gastric cancer (GC) is one of the leading causes of cancer death worldwide. The membrane glycoprotein CD200, widely expressed on multiple cells/tissues, uses a structurally similar receptor (CD200R), delivering immunoregulatory signals. There is evidence that CD200/CD200R signaling suppresses anti-tumor responses in different types of malignancies. Little is known about the CD200/CD200R pathway in GC. The aim of the study was to evaluate the frequencies of CD200+ and CD200R+ lymphocytes in patients with GC. MATERIAL AND METHODS: Forty patients primarily diagnosed with GC and 20 healthy volunteers (control group) were enrolled. The viable peripheral blood lymphocytes underwent labeling with fluorochrome-conjugated monoclonal antibodies and were analyzed using a flow cytometer. RESULTS: In the GC group, the percentages of T CD3+, CD3+/CD4+, and CD3+/CD8+ cells expressing CD200 antigen were higher than in the control group (p < 0.00013, p < 0.0004, and p < 0.0006, respectively). In the GC group, the frequencies of T CD3+, CD3+/CD4+ and CD3+/CD8+ cells expressing CD200R were lower than in the control group (p < 0.0009, p < 0.004, and p < 0.002, respectively). The percentage of B CD19+/CD200+ lymphocytes was higher in GC patients than in the control group (p < 0.00005). Lower frequency of B CD19+/CD200R+ cells was observed in GC patients compared to the control group (p < 0.0001). No differences in the frequencies of CD200+ and CD200R+ lymphocytes were found in relation to either UICC stage or histological grading of the tumors. CONCLUSIONS: For GC pathogenesis, deregulation of the CD200/CD200R axis is important. High percentages of lymphocytes with CD200 expression may contribute to the continuous T cell activation and development of chronic inflammation and influence gastric carcinogenesis. Termedia Publishing House 2018-05-21 2018-10 /pmc/articles/PMC6209723/ /pubmed/30393481 http://dx.doi.org/10.5114/aoms.2018.73398 Text en Copyright: © 2018 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Basic Research Zgodziński, Witold Grywalska, Ewelina Surdacka, Agata Zinkiewicz, Krzysztof Majewski, Marek Szczepanek, Dariusz Wallner, Grzegorz Roliński, Jacek Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title | Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title_full | Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title_fullStr | Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title_full_unstemmed | Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title_short | Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
title_sort | surface cd200 and cd200r antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy |
topic | Basic Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209723/ https://www.ncbi.nlm.nih.gov/pubmed/30393481 http://dx.doi.org/10.5114/aoms.2018.73398 |
work_keys_str_mv | AT zgodzinskiwitold surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT grywalskaewelina surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT surdackaagata surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT zinkiewiczkrzysztof surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT majewskimarek surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT szczepanekdariusz surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT wallnergrzegorz surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy AT rolinskijacek surfacecd200andcd200rantigensonlymphocytesinadvancedgastriccanceranewpotentialtargetforimmunotherapy |